Sugi Predict

Sugi Predict / Compounds / Omilancor

Omilancor

Omilancor

SCHEMBL29349469

O=C(c1cccc(-c2nc3ccccc3[nH]2)n1)N1CCN(C(=O)c2cccc(-c3nc4ccccc4[nH]3)n2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LANCL2 Q9NS86 1/20 1.00
▸ HRH4 Q9H3N8 1/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ SMN1; SMN2 Q16637 5/20 0.48
▸ RAB9A P51151 5/20 0.48
▸ NPC1 O15118 4/20 0.48
▸ KDM4E B2RXH2 4/20 0.48
▸ PKM P14618 3/20 0.48
▸ HPGD P15428 3/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ TP53 P04637 2/20 0.48
▸ HSD17B10 Q99714 2/20 0.48
▸ TSHR P16473 2/20 0.48
▸ LMNA P02545 2/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ MTOR P42345 1/20 0.48
▸ METAP2 P50579 1/20 0.48
▸ METAP1 P53582 1/20 0.48
▸ HTR2B P41595 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Omilancor SCHEMBL17706588 1.00 LANCL2 (1.00) LANCL2HRH4MEN1KMT2ASMN1; SMN2
SCHEMBL21043129 0.96 LANCL2 (0.93) LANCL2HRH4MEN1KMT2ASMN1; SMN2
SCHEMBL18805072 0.94 LANCL2 (0.88) LANCL2HRH4MEN1KMT2ASMN1; SMN2
SCHEMBL17705594 0.94 LANCL2 (0.88) LANCL2HRH4MEN1KMT2ASMN1; SMN2
SCHEMBL29466338 0.93 LANCL2 (0.86) LANCL2HRH4MEN1KMT2ASMN1; SMN2
SCHEMBL29063415 0.92 LANCL2 (0.84) LANCL2HRH4MEN1KMT2ASMN1; SMN2
SCHEMBL23561738 0.91 LANCL2 (0.83) LANCL2HRH4MEN1KMT2ASMN1; SMN2
SCHEMBL25310346 0.90 LANCL2 (0.81) LANCL2HRH4MEN1KMT2ASMN1; SMN2
SCHEMBL25311793 0.90 LANCL2 (0.80) LANCL2HRH4MEN1KMT2AHTR2B
SCHEMBL29466269 0.90 LANCL2 (0.80) LANCL2HRH4MEN1KMT2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4701663-A1 PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF Insilico Medicine IP Limited (HK) 2026-03-04 — — EP claimed
CN-119242189-A Double-sided adhesive tape special for computerized embroidery and processing equipment 江阴邦特新材料科技股份有限公司 2025-01-03 — — CN claimed
WO-2024222890-A1 PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2024-10-31 — — WO claimed
CN-117597327-A Pharmaceutical preparation 第一波动生物制药股份有限公司 2024-02-23 — — CN claimed
WO-2023147555-A2 METHODS OF TREATING PAIN ENDOSOME THERAPEUTICS, INC. (US) 2023-08-03 — — WO claimed
EP-3713096-B1 METHOD AND DEVICE FOR DECODING STAIRCASE CODE, AND STORAGE MEDIUM ZTE CORP (CN) 2023-07-12 — — EP claimed
US-20230107927-A1 METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS FIRST WAVE BIO, INC. 2023-04-06 — — US claimed
EP-4045480-A1 PHARMACEUTICAL FORMULATIONS First Wave Bio, Inc. (US) 2022-08-24 — — EP claimed
CN-217086114-U Automatic tuning device for piano 天津科技大学 2022-07-29 — — CN claimed
CN-110278076-B Block chain-based transparent data integrity auditing and transparent encrypted data duplicate removal method 电子科技大学 2022-06-03 — — CN claimed
EP-4735431-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2026-05-06 — — EP disclosed
EP-4735446-A1 SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 GILEAD SCIENCES, INC. (US) 2026-05-06 — — EP disclosed
US-12616135-B2 Variety corn line TPFX7814 SYNGENTA CROP PROTECTION AG (CH) 2026-05-05 — — US disclosed
US-20260114401-A1 VARIETY CORN LINE LDFF7914 SYNGENTA CROP PROTECTION AG (CH) 2026-04-30 — — US disclosed
US-20260114406-A1 VARIETY CORN LINE MEFX5118ZL SYNGENTA CROP PROTECTION AG (CH) 2026-04-30 — — US disclosed
CN-114195780-A Carbonyl heterocyclic compound and application thereof 上海医药集团股份有限公司 2022-03-18 — — CN disclosed
CN-114195806-A Carbonyl heterocyclic compound and application thereof 上海医药集团股份有限公司 2022-03-18 — — CN disclosed
US-20220072044-A1 THERAPIES WITH LANTHIONINE C-LIKE PROTEIN 2 LIGANDS AND CELLS PREPARED THEREWITH LANDOS BIOPHARMA, INC. (US) 2022-03-10 — — US disclosed
CN-114026104-A COT modulators and methods of use thereof 吉利德科学公司 2022-02-08 — — CN disclosed
CN-113952425-A Traditional Chinese medicine foot bath bag with functions of warming yang and soothing nerves and preparation method and application thereof 南京海德晟生物科技有限公司 2022-01-21 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220072044-A1 THERAPIES WITH LANTHIONINE C-LIKE PROTEIN 2 LIGANDS AND CELLS PREPARED THEREWITH LCP2, LANCL2, CALCB LANCL2 2/4885HRH4 4056/4885MEN1 2022/4885
US-20260114406-A1 VARIETY CORN LINE MEFX5118ZL INMT, CMBL, RNGTT LANCL2 3207/4885HRH4 3027/4885MEN1 861/4885
US-20260114401-A1 VARIETY CORN LINE LDFF7914 CDC14A, EHMT2, EHMT1 LANCL2 1734/4885HRH4 2361/4885MEN1 2010/4885
US-12616135-B2 Variety corn line TPFX7814 TM9SF4, ALPG, TM9SF3 LANCL2 4476/4885HRH4 2053/4885MEN1 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.